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ABSTRACT 
Introduction:  Prostate cancer (P ca) is the most commonly diagnosed visceral cancer worldwide. It is the 
second cause of cancer death in men. 
Objective: To study the impact of introducing transrectal ultrasound (TRUS)-guided biopsy in detection 
of Prostate cancer in Central Sudan. 
Methods: This was a retrospective hospital based study. A review was done for data of prostate cancer 
patients treated in the Institute of Nuclear Medicine and Oncology & Gezira Hospital of Renal Diseases & 
Surgery (GHRD&S), Wad Medani, Sudan during the years 2002-2007. Comparison was done between the 
data available before and after introduction of trans rectal ultrasound biopsy, TRUS in 2005. 
Results: Prostate cancer cases were contributing for only 8% of all cancers during the time period before 
TRUS introduction. During the year 2007 the figure increased to 14%. The leading cancer in males now is 
the P ca. previously it was the third registered cancer before TRUS was introduced. The detection of new 
cases per year increased dramatically after the introduction of TRUS service. 
Conclusion and recommendation: Prostate cancer was found to be the most common cancer in Sudanese 
males. TRUS guided biopsy contributed significantly in early detection of prostate cancer in this region. 
Distribution of this facility with adequate training of the staff optimizes a proper and early detection of 
prostate cancer. 
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INTRODUCTION 
Prostate cancer (Pca) is the second leading cause of cancer-related deaths among men in Western 
countries. The annual incidence rates in 2000 ranged between 19 and 55/100 000 men1, 2. 
Pca is already a major health and social problem, and it will become even more important due to 
the ageing of the population2. Although there are some differences in between countries, the 
incidence of Pca has been increasing over the years3. This increase has been suggested to result 
from improved detection of Pca following transurethral resection of the prostate (TURP) and more 
recently increased screening using Prostate Specific Antigen (PSA). Long life expectancy and 
environmental carcinogens contributed to the increased incidence4, 5. 
Early detection of Pca may help to reduce morbidity from prostate cancer, and prevent morbidity 
associated with urological dysfunction, bleeding, obstruction and pain associated with metastasis6. 
However, there are likely to be adverse effects e.g. anxiety associated with other outcomes of a 
screening test e.g. false positive, false negative and truly positive7. 
Widespread use of serum PSA has certainly increased prostate cancer detection resulting in a 
considerable stage migration8. Such results would not have been achieved without the 
contemporary refinements of the technique of prostate biopsy. After the initial introduction of the 
sextant biopsy technique by Hodge, little refinement of the technique was made until Stamey who 
introduced the TRUS 9, 10. 
Transperineal biopsy (TP) is unusual. Theoretically, the direction of transperineal biopsy might be 
better than transrectal (TR) route because they sample longitudinally the peripheral zone of the 
prostate. Initially transperineal route was demonstrated to be less accurate than TR in identifying 
hypo echoic lesion10, 11, and 13. 
Transrectal grey scale U/S guided biopsy is the standard method for diagnosing prostate cancer in 
patients with elevated PSA and/or abnormal digital rectal examination. Various biopsy strategies 
have been devised to increase the diagnostic yield of prostate biopsy, including sampling of visual 
abnormal areas, more lateral placement of biopsies, anterior biopsies and obtaining an increasing 
number of cores, ranging from- region sampling to saturation biopsies with up to 45 cores12, 13, 14, 
15. 
In Sudan the diagnosis of Pca is still not yet optimized , in Gezira hospital in Wad Medani there is 
a guide line adopted mandating the use of  TRUS biopsy, F/T PSA (free & total) and prostate acid 
phosphatase (PAP) were evaluated in Sudanese patients in study done in our centre 16. 
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PATIENTS AND METHODS 
This study was a retrospective cross sectional hospital based one, done through the combined clinic 
of Urology-oncology conducted by Institute of Nuclear Medicine and Oncology (INMO) and 
Gezira Hospital of Renal Diseases & Surgery (GHRD&S).all patients underwent TRUS biopsy in 
2005-2007 were included. The total number was 624 patients were enrolled. All underwent TRUS 
biopsy for the prostate. 
The European association of urology (EAU) guideline was adopted concerning inclusion and 
exclusion from the biopsies, with certain modifications according to the facilities available for us.  
We used to estimate PSA for all patients with lower urinary tract symptoms (LUTS) over 50 years 
old, any patients with prostatic enlargement and abnormal DRE examination and/or recurrent 
prostate. TRUS was provided by the International Urology Association auspice by professor. 
Khalaf, hence TRUS Biopsy with sextant cores biopsy under local anesthesia or local infiltration 
with lidocaine were taken   
The indication for TRUS biopsy was for cases of PSA more than 4 ng/L, for cases with abnormal 
DRE even with PSA less than 4 ng/L and/or for recurrent prostate. 
All biopsies were sent to the histopathology department, repeated biopsies were conducted in 
certain conditions where the results were apparently paradoxical to the clinical and PSA results. 
Biopsy delivery to the histopathology was the responsibility of patients themselves.  
Once the diagnosis was established, the patients were referred to the combined clinic. All patients 
were addressed and treated in the combined clinic except those who either missed or also defaulted 
or Salk medical advice in another center. 
Preparation of the patients was done at the outpatient clinic including; enema, explaining the 
procedure, local anesthesia and local care. A training course was conducted to optimize the skill 
of the staff for the procedure .prophylactic antibiotic was a routine prior to the procedure. Minor 
analgesia and antibiotics were given after the biopsy. There was no mortality due to the procedure. 
Data of the patients were kept in both hard and soft copies in the registry of the hospital. Records 
were reviewed for cancer prostate registry   in INMO for year 2002 to 2007.  Analysis of data was 
done through SPSS and different ANOVA tests were used. 
RESULTS 
In the 2005 and mid half of 2006, 75 cases were performed. In the last half of 2006 after the avail 
of TRUS, 238 were done with approximate 53 new cases been discovered and referred to the 
combined urology-oncological clinic.  During 2007, 311 cases of TRUS biopsies were done and 
the number of diagnosed cancer cases was 65. (table1). 
 EDITORIAL  
 
Gezira Journal Of Health Sciences 2001 vol.6(1)  
 
Gezira Journal of Health Sciences 2001 vol.6 (1) 
Table 1: Percentage of prostate cancer in relation to total male cancers INMO(2002-2007) 
years Number of prostate cancer(%from male cancers) 
2002 13 (8.1) 
2003 16 (8.4) 
2004 18 (8.3) 
2005 27 (9.5) 
2006 53 (14.6) 
2007 65 (17.3) 
 
We recognized several causes of incompliant patients who disappeared either because of financial 
impact or unawareness so part of the results may be missed from the records. 
The morbidity of the procedure included minor anal pain, haematuria in some cases and haemato- 
spermia no mortality. 
Fig.1: Total number of Prostate cancer cases in years 2002-2007. INM 
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Fig.2: Prostate cancer in relation to the most common male cancers- INMO 
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Prostate cancer ranked number two in the top 10 commonest cancers in males treated at INMO, 
this had been the case for years 2002-2004 which a lone constitutes 18(8.3 %). In 2005 the prostate 
cancer took the lead 27(9.5 %), and continued through years 2006 with peak in 2007 (65/17.3%).. 
While the non-Hodgkin lymphomas and nasopharyngeal cancers remained fluctuating within 
small range of frequency through the study period. There was a surge in the number of cases 
diagnosed having prostate cancer in the years 2005-2007 (Figure 2).  
Prostate cancer has been detected with increasing frequency, due in part to the widespread 
availability of serum prostate specific antigen (PSA) testing. Incidence was static between 2002 
and 2005, has been rising in percentage annually since 2005, and peaked in 2007(figure 2 & table 
1).  
 
DISCUSSION   
Prostate cancer (Pca) is recognized as one of the major health problem facing the male 
population17. The incidence rate has risen steadily over the last 15 years, although the degree to 
which this rise reflects increased detection and/or a true increase in risk remains uncertain18. Data 
from the United State, Africa and the Caribbean demonstrate that significant ethnic variations for 
prostate cancer risk exist, the incidence rates for American Black is 55% greater than white18, 19, 
20.   
Historically (1967-1984), Pca was not considered among the top 10 commonest cancers in Sudan 
as reported by Hamad 21. Recently in the period 1984-2004 the prostate cancer was at the bottom 
of the top 10 common male cancer22. 
 With the advent of prostate specific antigen PSA the number of patients whom underwent prostate 
biopsy had dramatically increased. Other possible factors may include awareness of the population 
and improvement in other diagnostic techniques like ultrasound, CT and MRI. The sextant biopsy 
technique has been conventionally used for the diagnosis of prostate cancer22. The inauguration of 
Gezira Hospital for Renal Diseases and Surgery (GHRD&S) was in 2005 availed the introduction 
of trans rectal ultrasound (TRUS). Before this time blind transrectal biopsies were used for 
establishing a diagnosis of prostate cancer.  
Before the inauguration of GHRD&S and the introduction of regular prostate specific antigen 
(PSA) assessment and trans-rectal ultrasound (TRUS) guided Biopsy, the diagnosis of prostate 
cancer used to be furnished through crude circumstantial evidence based on clinical work up & 
digital rectal examination. The biopsy provided for the pathologist through the rectum guided by 
just the finger using tru-cut needle blindly taking one or two cores from either firm, nodular and 
or randomly elsewhere from the prostate lobes. Also from patients underwent open prostatectomy 
or (TURP) as a treatment of benign prostate hyperplasia. 
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The total number of patients underwent TRUS biopsy was 624 only 145 of them with 
histopathological evidence of cancer. This as yet never tell the exact number of new cases because 
still the biopsies were served  by the patients themselves  or their  relatives to be handled to the 
histopathology. Therefore a significant number of cases were lost by the problems such as 
negligence, poor compliance, financial drawback, poor counseling and movement of patients to 
another hospital inside or abroad. 
Medical insurance is available to shoulder the expenses of this procedure to a large sector of 
patients. We provide this service with devaluated cost and even free for patients confirmed not 
affording it. 
Before the introduction of TRUS services, prostate cancer the 5th cancer in cancer registry in 
INMO, but after 2005 it rose from 8.1% in 2002 to 14.6% in 2006 and 17.3% in 2007. Still the 
problem of unique system of registry, referral format and the methods used for the diagnosis is to 
be addressed in order to furnish an optimal detection rate of cancer. Is this the final picture for PCa 
in this region of Sudan? It is early to answer this but, still many patients doesn't have access to 
undergo TRUS-guided biopsy and need not to forget that TRUS in many hands has a low 
sensitivity23, 24.  
The other important point which needs more in depth review is to look for the benefit of TRUS- 
guided biopsy in improving stage at presentation. 
 
CONCLUSION& RECOMMENDATIONS 
Pca is quite common in Sudan and many cases were and will remain undetected. Optimizing 
diagnostic services will enhance early diagnosis.  
Further studies to discover potential risk factors for PCa in Sudan are recommended. 
 TRUS biopsy services improved the rate of cancer detection in GHRD&S 
 
REFERENCES 
1- Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch 
G. Cancer of the prostate. Crit Rev Oncol Hematol. 2005 Dec; 56(3):379-96. 
2- Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani, Frédéric Staerman, Claude C 
Schulman. What's New in Prostate Cancer: Highlights from Urologic and Oncologic 
Congresses- 2006. European Urology; 2007; 6(4):404-412 
3- Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence 
and mortality. Int J Cancer. 2000 Jan 1;85(1):60-7. 
 
4- Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate 
cancer. Cancer Control; 2006; 13(3):158-68. 
5- Nicolas Mottet, Jack A. Schalken, Axel Heidenreich, Patrick J. Bastian, Jacques Irani, Laurent 
Salomon, Michel Soulié. Highlights on Prostate Cancer from Urological and Oncological 
Congresses in 2007. European Urology;  2008; 7 (6): 460-476. 
6- Melia J. Part 1: The burden of prostate cancer, its natural history, information on the outcome 
of screening and estimates of ad hoc screening with particular reference to England and Wales. 
BJU international; 2005; 95: 4-15.  
 EDITORIAL  
 
Gezira Journal Of Health Sciences 2001 vol.6(1)  
 
Gezira Journal of Health Sciences 2001 vol.6 (1) 
7- Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific 
antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. 
J Urol; 2004; 172(4 Pt 1):1297-301. 
8- Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, Myles J, 
Reuther AM, Klein EA. Continuing trends in pathological stage migration in radical 
prostatectomy specimens. Urol Oncol; 2004; 22(4): 300-306. 
9- Stamey TA. Making the most out of six systematic sextant biopsies. Urology; 1995; 45(1): 2-
12. 
10- Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation 
prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of 
the literature. Eur Urol; 2007; 52(5):1309-22.  
11- Terris MK, Hammerer PG, Nickas ME. Comparison of ultrasound imaging in patients 
undergoing transperineal and transrectal prostate ultrasound. Urology; 1998; 52(6):1070-2. 
12- Pelzer AE, Bektic J, Berger AP, Halpern EJ, Koppelstätter F, Klauser A, Rehder P, Horninger 
W, Bartsch G, Frauscher F. Are transition zone biopsies still necessary to improve prostate 
cancer detection? Results from the tyrol screening project. Eur Urol; 2005; 48(6):916-21. 
13- Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed 
ultrasound guided transrectal core biopsies of the prostate. J Urol; 1989; 142(1): 71-74. 
14- Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of 
the peripheral zone for prostate cancer detection. J Urol; 1998; 160(6 1): 2111-2114. 
15- Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to 
sextant method for diagnosing carcinoma of the prostate. J Urol; 1997; 157(1): 199-202.  
16- Fatima A, Elimam M, Khalid E, Nasr Eldin M, Omran M, Eltom K. The utility of free and 
total prostate specific antigen and prostatic acid phosphatase 
 EDITORIAL  
 
Gezira Journal Of Health Sciences 2001 vol.6(1)  
 
Gezira Journal of Health Sciences 2001 vol.6 (1) 
     as tumor markers in Sudanese patients with prostate enlargement. Journal of     the Arab Board 
of Medical Specialization 2005; 7(3): 255-59.  
17- Axel H. Gunnar A, Michel C B. et al. EAU Guidelines on prostate cancer European Urology; 
2008; 53: 68-80. 
18- Yoar B Simon E, Fowzia I. et al. The risk of Pca amongst black men in the U.K, European 
Urology; 2008; 53: 99-105. 
19- Parkin Dm, Ferlay J, Hamdi cherif  M. et al. Cancer in Africa, epidemiology & prevalence. 1st 
ed. Lyon (France). LARC scientific publication No. 153:2003. 
20- AUS G, Abbou CC, Bolla M, et al. EAU Guidelines in Pca. Euroopean Urology; 2005; 48: 
546-51. 
21- Hamad HMA. Cancer initiative in Sudan. Annals of Oncol; 2006; 17 (suppl 8): viii32-36. 
22- Gupta NP, Ansari MS, Dass SC. TRUS guided biopsy for detecting early prostate cancer: An 
Indian experience. India J Cancer; 2005; 42: 151-154. 
23- Terris MK, Freiha FS, McNeal JE, Stamey TA (1991) Efficiacy of transrectal ultrasound for 
identification of clinically undetected prostate cancer. J Urol 146:78. 
Norberg M, Egevad L,Holmberg L, Sparen P, Norlen B J, Busch C (1997) The sextant protocol 
for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 
50:562–566 
 
 
